Novartis (VTX:NOVN) has been given a CHF 80 price objective by equities researchers at Barclays in a research report issued to clients and investors on Thursday, September 20th. The brokerage currently has a “neutral” rating on the stock. Barclays’ price objective indicates a potential upside of 2.07% from the stock’s previous close.
A number of other research analysts also recently issued reports on the company. UBS Group set a CHF 80 price target on Novartis and gave the company a “neutral” rating in a report on Thursday, July 19th. Credit Suisse Group set a CHF 80 price objective on Novartis and gave the company a “neutral” rating in a research report on Thursday, July 19th. HSBC set a CHF 79 price objective on Novartis and gave the company a “neutral” rating in a research report on Tuesday, May 29th. Goldman Sachs Group set a CHF 86 price objective on Novartis and gave the company a “neutral” rating in a research report on Friday, June 29th. Finally, Jefferies Financial Group set a CHF 100 price objective on Novartis and gave the company a “buy” rating in a research report on Wednesday, July 18th. Eleven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of CHF 88.57.
Shares of VTX NOVN traded up CHF 0.34 during mid-day trading on Thursday, hitting CHF 78.38. 11,210,000 shares of the stock traded hands, compared to its average volume of 5,980,000. Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.
Novartis Company Profile
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Further Reading: Google Finance
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.